The SEC and the U.S. Attorney's Office, New Jersey, brought
civil and criminal insider trading charges against, respectively, six and seven
individuals based on a five year insider trading ring that garnered over $1.4
million in illegal profits. Three of the individuals are executives at
pharmaceutical companies. Several been friends since high school. Overall there
were ten tippees At the center of the trading was four take-over transaction
and six earnings releases which spawned trading tracing to 2007 and continuing
through mid-2012. Elaborate steps were taken to conceal the trading. Those
steps failed. SEC v. Lazorchak, Case No. 2:12-cv-07164 (D.N.J. Filed
Nov. 19, 2012).
The Commission's complaint named as defendants: John
Lazorchak, Director of Financial Reporting at pharmaceutical company Celgene
Corporation; Mark Cupo, Director of Accounting at Sanofi-Aventis Corporation,
another pharmaceutical company and a former co-worker of Mr. Lazorchak; Mark
Foldy, employed in the marketing department at a third pharmaceutical company,
Styker Corporation; Michael Castelli, a friend of defendant Cupo; Lawrence
Grum, who holds a brokers license and attended high school with defendant
Castelli; Michael Pendolino; and James Deprado who is not named as a defendant
in the criminal case. Defendants Larzorchak, Pendolino, Foldy and Deprado
attended the same high school.
The ring is alleged to have traded on inside information
in advance of four corporate take-over announcements:
Insider trading also is alleged to have occurred prior to
the announcement by Celgene that it was withdrawing an application from the
European Medicines Agency's Committee on June 21, 2012 and earnings
announcements for the quarters ended: September 30, 2009; March 31, 2010; June
30, 2010; September 30, 2010; June 30, 2011; and March 31, 2012.
The basic scheme involved an arrangement devised by
Messrs. Castelli and Grum. It called for Mr. Lazorchak, through defendant Cupo,
to furnish them inside information obtained from his position at Celgene. Mr.
Cupo served only as a middleman. Defendants Castelli and Grum placed the
trades, often in options. Mr. Cupo would be compensation for his role.
The idea behind the scheme was to separate the source of
the information from the securities transactions to conceal the activity. Other
steps were also taken to avoid detection. The members of the scheme typically
interacted with Mr. Cupo in person. The traders also purchased Celgene
securities at times when then did not have inside information. In some cases
they sold portions of their holdings in advance of the corporate announcement.
The traders also created contemporaneous research files and e-mails regarding
the transactions to justify the trades.
Over time the scheme expanded. Mr. Lazorchak illegally
tipped Messrs. Pendolino and Foldy and was in turn compensated by them. Messrs.
Pendolino also tipped others as the number of tippees multiplied.
At the outset of the scheme FINRA identified the trading
of Messrs. Foldy and Pendolino following the acquisition of Pharmion by Celgene.
The regulator circulated a questionnaire to executives at Celgene asking that
they specify if they knew anyone on a list of names which included Messrs.
Foldy and Pendolino. Mr. Lazorchak falsely reported that he did not know either
man. He later informed both men along with defendant Cupo about the FINRA
questionnaire and his actions. Mr. Cupo reassured the group that their plan
would evade detection, a step he took repeatedly according to the SEC.
The Commission's complaint alleges violations of Exchange
Act Sections 10(b) and 14(e) and Securities Act Section 17(a). Each defendant
in the criminal case is charged with multiple counts including conspiracy and
securities fraud. The defendants voluntarily surrendered in the criminal
action. Both cases are pending.
Hurricane Sandy: As
we prepare to give thanks with family and friends this Thanksgiving please
remember the victims of Sandy with a donation to the Red Cross (here).
For more cutting edge commentary on
developing securities issues, visit SEC Actions, a
blog by Thomas Gorman.
For more information about LexisNexis
products and solutions connect with us through our corporate site.